Methods and compositions for treating a subject for central nervous system (CNS) injury
Methods for treating a central nervous system (CNS) injury in a subject are provided. Aspects of the methods include administering to the subject an effective amount of gamma aminobutyric acid (GABA) receptor signaling inhibitor to treat the subject for the CNS injury. Also provided are compositions finding use in embodiments of the methods. Methods and compositions of the invention find use in the treatment of a variety of different CNS injuries, including but not limited to, treating a subject for CNS injury associated with the occurrence of stroke.
1. A method of treating one or more pathological injuries selected from the group consisting of a stroke and ischemic brain damage in a subject, the method consisting of:
administering to the subject an effective amount of a gamma aminobutyric acid (GABA) receptor signaling inhibitor that inhibits signaling from an α5 subunit containing GABA receptor or that inhibits signaling from a δ subunit containing GABA receptor, wherein the pathological injury is characterized by the presence of physically damaged or altered CNS tissue, wherein the administration does not begin until three days after the pathological injury occurs, and wherein the inhibitor is selected from the group consisting of:
6,6-Dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one;
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the GABA receptor signaling inhibitor is:
3. The method according to claim 1 , wherein the subject is a human subject.
4. The method according to claim 1 , wherein the stroke is ischemic stroke or hemorrhagic stroke.
5. The method according to claim 4 , wherein the stroke is characterized by increased GABA receptor signaling in peri-infarct tissue.
6. A method of treating one or more pathological injuries selected from the group consisting of a stroke and ischemic brain damage in a human patient, the method consisting of:
diagnosing the patient as having the pathological injury and then administering to the patient having the injury an effective amount of a gamma aminobutyric acid (GABA) receptor signaling inhibitor that inhibits signaling from an α5 subunit containing GABA receptor or that inhibits signaling from a δ subunit containing GABA receptor, wherein the administration does not begin until three days after the pathological injury occurred, and wherein the inhibitor is selected from:
6,6-Dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one;
or a pharmaceutically acceptable salt thereof.
7. The method according to claim 6 , wherein the GABA receptor signaling inhibitor is:
8. The method according to claim 6 , wherein the subject is a human subject.
9. The method according to claim 6 , wherein the stroke is ischemic stroke or hemorrhagic stroke.
10. The method according to claim 9 , wherein the stroke is characterized by increased GABA receptor signaling in peri-infarct tissue.
11. A method of treating one or more pathological injuries selected from the group consisting of a, stroke and ischemic brain damage in a human patient, the method consisting of: assessing the subject for peri-infarct tissue repair and then administering to the patient an effective amount of a gamma aminobutyric acid (GABA) receptor signaling inhibitor that inhibits signaling from an a5subunit containing GABA receptor or that inhibits signaling from a d subunit containing GABA receptor, wherein the administration does not begin until three days after the pathological injury occurred, and wherein the inhibitor is selected from:
6,6-Dimethyl-3-(2-hydroxyethyl)thio-1-(thiazol-2-yl)-6,7-dihydro-2-benzothiophen-4(5H)-one;
or a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 , wherein the GABA receptor signaling inhibitor is:
13. The method according to claim 11 , wherein the subject is a human subject.
14. The method according to claim 11 , wherein the stroke is ischemic stroke or hemorrhagic stroke.
15. The method according to claim 14 , wherein the stroke is characterized by increased GABA receptor signaling in peri-infarct tissue.